– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – “Huntington’s Disease is a devastating, progressive movement disorder with no cure and no approved therapeutic options available to ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
15hon MSN
Why some lung transplant patients face higher rejection risk: Study points to key genetic variant
About one third of lung transplant recipients have a genetic variant that makes them more likely to develop chronic lung ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
...CR2-fH substantially reduced disease activity and joint damage... An inhibitor of the alternative pathway (AP) of complement activation reduces clinical disease activity and joint damage in an ...
Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...
Studies by researchers at Columbia University Irving Medical Center suggest that one of the immune system’s oldest branches, the complement system, and coagulation dysfunction, may be influencing the ...
In a recent study published in Molecular Psychiatry, researchers review the anti-inflammatory effects of ketamine in the peripheral and central nervous systems. To this end, all relevant articles were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback